Mitochondrial Dynamics Modulators for Parkinson's Disease

Migration, Crosslink

📖

Mitochondrial Dynamics Modulators for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-mitochondrial-dynamics

📖 Wiki Page

therapeutic1163 wordssynced 2026-04-02

Mitochondrial Dynamics Modulators for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Mitochondrial Dynamics Modulators for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Process</td>
<td>Proteins</td>
</tr>
<tr>
<td class="label">Fission</td>
<td>[Drp1](/genes/drp1) (DNM1L), Fis1, Mff, MiD49/50</td>
</tr>
<tr>
<td class="label">Fusion</td>
<td>Mfn1, Mfn2, [OPA1](/genes/opa1)</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company/Group</td>
</tr>
<tr>
<td class="label">Mdivi-1</td>
<td>Various Academic</td>
</tr>
<tr>
<td class="label">P110</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Drp1i</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Dynasore</td>
<td>Research</td>
</tr>
<tr>
<td class="label">DDR1-IN-1</td>
<td>Industry</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Group</td>
</tr>
<tr>
<td class="label">SIRT1 activators</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">OPA1 agonists</td>
<td>Industry</td>
</tr>
<tr>
<td class="label">Mfn1/2 gene therapy</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Bezafibrate</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">MPTP mice</td>
<td>Mdivi-1</td>
</tr>
<tr>
<td class="label">6-OHDA rats</td>
<td>Drp1 siRNA</td>
</tr>
<tr>
<td class="labe

...

Mitochondrial Dynamics Modulators for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Mitochondrial Dynamics Modulators for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Process</td>
<td>Proteins</td>
</tr>
<tr>
<td class="label">Fission</td>
<td>[Drp1](/genes/drp1) (DNM1L), Fis1, Mff, MiD49/50</td>
</tr>
<tr>
<td class="label">Fusion</td>
<td>Mfn1, Mfn2, [OPA1](/genes/opa1)</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company/Group</td>
</tr>
<tr>
<td class="label">Mdivi-1</td>
<td>Various Academic</td>
</tr>
<tr>
<td class="label">P110</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Drp1i</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Dynasore</td>
<td>Research</td>
</tr>
<tr>
<td class="label">DDR1-IN-1</td>
<td>Industry</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Group</td>
</tr>
<tr>
<td class="label">SIRT1 activators</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">OPA1 agonists</td>
<td>Industry</td>
</tr>
<tr>
<td class="label">Mfn1/2 gene therapy</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Bezafibrate</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">MPTP mice</td>
<td>Mdivi-1</td>
</tr>
<tr>
<td class="label">6-OHDA rats</td>
<td>Drp1 siRNA</td>
</tr>
<tr>
<td class="label">α-synuclein transgenic</td>
<td>Mfn1 overexpression</td>
</tr>
<tr>
<td class="label">PINK1 knockout</td>
<td>Drp1 inhibition</td>
</tr>
</table>

Mitochondrial dynamics refers to the continuous processes of mitochondrial fission (division) and fusion (joining), which maintain mitochondrial quality and function. In [Parkinson's disease](/diseases/parkinsons-disease), these processes are severely dysregulated, leading to fragmented mitochondria, impaired energy production, and ultimately neuronal death. Targeting the proteins controlling fission and fusion offers promising neuroprotective strategies[@chandra2019].

Dopaminergic neurons in the substantia nigra pars compacta have particularly high energy demands and are especially vulnerable to [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction-parkinsons). The balance between fission and fusion is critical for:

Maintaining mitochondrial morphology and distribution
Ensuring adequate ATP production through oxidative phosphorylation
Facilitating quality control via mitophagy
Distributing mitochondria throughout neuronal processes
Regulating calcium homeostasis

Scientific Rationale

Key Proteins in Mitochondrial Dynamics

Mermaid diagram (expand to render)

Drp1 in Parkinson's Disease

[Drp1](/genes/drp1) (Dynamin-related protein 1) is a GTPase that catalyzes mitochondrial fission[@flippo2018]:

Recruitment mechanism: Drp1 is recruited to mitochondria via adaptor proteins (Mff, Fis1, MiD49/50) that anchor it to the outer mitochondrial membrane
GTP hydrolysis: Drp1 assembles into rings around mitochondria and undergoes GTP hydrolysis, causing constriction and fission
PD dysregulation: In PD models, Drp1 is overactivated, leading to excessive fission and mitochondrial fragmentation
Pathogenic mechanisms: Drp1 overactivation is linked to:
PINK1/Parkin pathway dysfunction
LRRK2 mutations
Alpha-synuclein toxicity
Environmental neurotoxins (MPTP, 6-OHDA)

Fusion Proteins in PD

Mitofusins (Mfn1, Mfn2) and OPA1 mediate mitochondrial fusion:

Mfn1/Mfn2: Outer membrane fusion proteins that mediate tethering and merging of mitochondrial outer membranes
OPA1: Inner membrane fusion protein that maintains cristae structure and inner membrane integrity
PD dysfunction: Reduced fusion activity in PD leads to impaired mitochondrial networks and quality control
Therapeutic potential: Enhancing fusion can compensate for fission excess and restore mitochondrial function

Therapeutic Rationale

Modulating mitochondrial dynamics can[@burté2015]:

Restore mitochondrial morphology: Normalize fission/fusion balance

Improve energy production: Enhance oxidative phosphorylation efficiency

Enhance quality control: Improve mitophagy efficiency and mitochondrial turnover

Protect against neurotoxins: Confer resistance to MPTP, 6-OHDA, and other PD insults

Reduce oxidative stress: Decrease ROS production from dysfunctional mitochondria

Drug Development

Drp1 Inhibitors

Mechanism of action: Drp1 inhibitors work by:

Blocking GTPase activity of Drp1

Preventing mitochondrial recruitment

Reducing excessive fission

Restoring network morphology and function

Fusion Promoters

Emerging Approaches

Phosphorylation modulators: Targeting Drp1 phosphorylation at Ser616 (pro-fission) or Ser637 (anti-fission)
Allosteric modulators: Targeting protein-protein interactions between Drp1 and its adaptors
Small molecule Mfn agonists: Direct activators of mitofusin proteins

Preclinical Evidence

In Vitro Models

Drp1 inhibition protects dopaminergic neurons against MPTP toxicity
Mfn1 overexpression rescues mitochondrial dysfunction in PINK1 knockdown cells
OPA1 enhancement improves mitochondrial function in alpha-synuclein models

In Vivo Evidence

Clinical Status

No mitochondrial dynamics modulators are currently in PD clinical trials. This remains an important area for drug development.

Key Challenges

Brain penetration: Many Drp1 inhibitors fail to reach therapeutic concentrations in the CNS

Selectivity: Off-target effects can complicate therapeutic windows

Therapeutic window: Narrow margin between efficacy and toxicity

Timing: Optimal intervention window in disease progression unclear

Biomarkers: Lack of biomarkers for target engagement

Ongoing Research

Development of brain-penetrant Drp1 inhibitors
Exploration of combination therapies targeting multiple aspects of mitochondrial dysfunction
Identification of patient subsets who may benefit most from mitochondrial targeting

Integration with Other PD Pathways

Connection to PINK1/PARKIN

The [PINK1/PARKIN mitophagy](/mechanisms/pink1-parkin-mitophagy-pathway-parkinsons) pathway requires proper mitochondrial dynamics[@wang2019]:

Excessive fission impairs PINK1 accumulation on damaged mitochondria
Restoring dynamics enhances mitophagy efficiency
Combined targeting may provide synergistic benefit

Synergy with LRRK2

[LRRK2](/genes/lrrk2) mutations affect mitochondrial function:

LRRK2 regulates Drp1 localization and activity
Combined approaches targeting both LRRK2 and mitochondrial dynamics may enhance benefit

Connection to GBA

[GBA](/genes/gba) mutations impair lysosomal function:

Lysosomal dysfunction affects mitochondrial quality control
Mitochondrial dynamics modulators may help compensate

Biomarkers for Target Engagement

Mitochondrial morphology: Live cell imaging of neurons
Drp1 phosphorylation: p-Ser616 Drp1 levels in blood/CSF
ATP production: Seahorse analysis of cellular respiration
ROS levels: MitoSOX imaging in patient-derived cells

Future Directions

Research Priorities

Development of brain-penetrant Drp1 inhibitors with optimal pharmacokinetics

Validation of biomarkers for target engagement

Exploration of combination therapy approaches

Identification of patient subsets most likely to benefit

Clinical Trial Design Considerations

Early-stage patients likely to benefit most
Biomarker-enriched enrollment
Extended treatment duration to assess disease modification

References

[Knott AB et al., Mitochondrial dynamics in neurodegeneration (2008)](https://doi.org/10.1038/nrn2297)

[Reddy PH et al., Drp1 inhibition in PD models (2011)](https://doi.org/10.1016/j.neurobiolaging.2011.02.014)

[Gomez-Lopez et al., Mitochondrial dynamics as therapeutic target (2021)](https://doi.org/10.1002/mds.28470)

[Berthet A et al., Drp1 and mitochondrial dysfunction in PD (2014)](https://doi.org/10.1038/ncomms4342)

[Chandra R et al., Mitochondrial dynamics in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31295467/)

[Burté F et al., Mitochondrial dynamics in neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/25827640/)

[Flippo KH et al., Drp1 in neuronal death and survival (2018)](https://pubmed.ncbi.nlm.nih.gov/29395678/)

[Wang W et al., Mitochondrial dynamics in dopaminergic neurons (2019)](https://pubmed.ncbi.nlm.nih.gov/30626962/)

[Ono K et al., Mitochondrial dynamics in neurodegeneration (2014)](https://doi.org/10.1111/jnc.12732)

[Santos MS et al., Mitochondrial dysfunction and neurodegenerative disorders (2010)](https://doi.org/10.2174/156720510793611619)

[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses](/hypothesis/h-43f72e21) — 0.72 · Target: PRKAA1
[Stress Granule Phase Separation Modulators](/hypothesis/h-97aa8486) — 0.71 · Target: G3BP1
[Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement](/hypothesis/h-fd1562a3) — 0.69 · Target: COX4I1
[TFAM overexpression creates mitochondrial donor-recipient gradients for directed organelle trafficki](/hypothesis/h-98b431ba) — 0.64 · Target: TFAM
[Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators](/hypothesis/h-ba3a948a) — 0.63 · Target: CX3CR1
[Senescent Cell Mitochondrial DNA Release](/hypothesis/h-1a34778f) — 0.60 · Target: CGAS/STING1/DNASE2
[Mitochondrial-Lysosomal Contact Site Engineering](/hypothesis/h-0791836f) — 0.59 · Target: RAB7A

Related Analyses:

[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
[Mitochondrial transfer between astrocytes and neurons](/analysis/SDA-2026-04-01-gap-v2-89432b95) 🔄
[Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄
[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-mitochondrial-dynamics-modulators-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-mitochondrial-dynamics-modulators-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-c37d2e639958
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-mitochondrial-dynamics-modulators-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

104

Outgoing

144

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Mitochondrial Dynamics Modulators for Parkinson's Disease

Mitochondrial Dynamics Modulators for Parkinson's Disease

Overview

Mitochondrial Dynamics Modulators for Parkinson's Disease

Overview

Scientific Rationale

Key Proteins in Mitochondrial Dynamics

Drp1 in Parkinson's Disease

Fusion Proteins in PD

Therapeutic Rationale

Drug Development

Drp1 Inhibitors

Fusion Promoters

Emerging Approaches

Preclinical Evidence

In Vitro Models

In Vivo Evidence

Clinical Status

Key Challenges

Ongoing Research

Integration with Other PD Pathways

Connection to PINK1/PARKIN

Synergy with LRRK2

Connection to GBA

Biomarkers for Target Engagement

Future Directions

Research Priorities

Clinical Trial Design Considerations

References

See Also

💬 Discussion

📗 Cite This Artifact

Mitochondrial Dynamics Modulators for Parkinson's Disease

Mitochondrial Dynamics Modulators for Parkinson's Disease

Overview

Mitochondrial Dynamics Modulators for Parkinson's Disease

Overview

Scientific Rationale

Key Proteins in Mitochondrial Dynamics

Drp1 in Parkinson's Disease

Fusion Proteins in PD

Therapeutic Rationale

Drug Development

Drp1 Inhibitors

Fusion Promoters

Emerging Approaches

Preclinical Evidence

In Vitro Models

In Vivo Evidence

Clinical Status

Key Challenges

Ongoing Research

Integration with Other PD Pathways

Connection to PINK1/PARKIN

Synergy with LRRK2

Connection to GBA

Biomarkers for Target Engagement

Future Directions

Research Priorities

Clinical Trial Design Considerations

References

See Also

Related Hypotheses

💬 Discussion